Gilead Sciences' $1.275 billion upfront investment in an oral peptide program from PepStar Therapeutics highlights growing big pharma interest in oral peptide therapies, even at early development stages. This puts a spotlight on companies like Entera Bio, which is advancing its oral peptide EB613 for osteoporosis into Phase 3 with promising patient efficacy data and secured funding. The article suggests that Entera's N-Tab platform, designed to enable oral delivery of complex peptides, could unlock broader markets for bone-building treatments and other conditions.
Life SciencesFinancial MarketsMergers And AcquisitionsGILD
BondBloxx's JPMorgan USD Emerging Markets 1-10 Year Bond ETF (XEMD) has achieved over $1 billion in assets under management, four years after its launch, contributing to BondBloxx's total assets of more than $8.5 billion. The ETF invests in U.S. dollar-denominated emerging-market sovereign bonds with shorter durations, aiming to offer diversification and income while mitigating direct foreign currency risk and reducing interest rate sensitivity compared to broader strategies. While emerging market debt provides growth exposure, investors should be aware of risks related to sovereign creditworthiness and global financial conditions.
The Benjamin Chambers Elementary PTO received a donation of hygiene products from the Ulta Beauty Distribution Center for its Winter Clothing Drive. The PTO publicly thanked Christine from the distribution center for her contribution. This donation will support the local community initiative.
T. Rowe Price Group (TROW) is expected to report Q3 2026 earnings of $2.65 per share on revenue of $1.98 billion on October 29. The EPS consensus has slightly declined over the past 30-90 days, indicating modest tempering of analyst expectations. While revenue is projected to grow year-over-year, EPS is expected to decline by 5.7%, suggesting potential margin compression or increased expenses.
Oct 26, 2026, 10:51 a.m. EDT2 min readSouth Korea is leaning toward delaying its tax on crypto gains for a fourth time. (Jakub Żerdzicki/Unsplash)SummarySouth Korea is leaning toward delaying its crypto gains...
Michael Burry is still short Palantir heading into Monday's earnings report, and with shares priced at over 120 times forward earnings, one soft data point could hand skeptics exactly the opening they need.
Timothy P. Eckersley, an officer at Allegion plc, has filed a Form 144 notice proposing the sale of 6,364 common shares of ALLE, valued at approximately $1.14 million. These shares were acquired on February 5, 2025, through restricted stock vesting as compensation. The approximate sale date is listed as October 26, 2026, with Fidelity Brokerage Services LLC named as the broker.
Texas Instruments (NASDAQ: TXN) has demonstrated significant outperformance over the past two decades, yielding an average annual return of 11.97%. An initial investment of $1000 in TXN stock 20 years ago would now be valued at $9,527.53, highlighting the substantial impact of compounded returns. The company currently holds a market capitalization of $255.25 billion.
Barclays PLC has notified Mobico Group PLC of a major holding, indicating an acquisition or disposal of voting rights. The notification shows that Barclays PLC now holds a total of 6.15% of the voting rights in Mobico Group PLC, comprising both direct voting rights and voting rights through financial instruments, with the threshold crossed on October 22, 2026. This represents an increase from their previous notification of 5.84%.
AstraZeneca PLC has notified a change in its major holdings in NIOX Group PLC, crossing a threshold on October 22, 2026. This change resulted from an acquisition or disposal of voting rights and a change in the Issuer's total voting rights following a tender offer. AstraZeneca PLC now holds 16.31% of the voting rights in NIOX Group PLC, amounting to 66,093,108 shares.
This article reports on Boston Omaha Corp.'s (BOC) Form 8K filing for October 26th. Form 8K is a crucial document that public companies file with the SEC to announce major events that shareholders should know about. The specific details of the filing are not included in this brief report.
Peter J. Federico, an officer and director at AGNC Investment Corp., intends to sell 67,794 common shares valued at $601,357.52 on or around October 26, 2026. This planned sale follows a previous sale of the same number of shares on October 23, 2026, for approximately $602,688.66. The shares to be sold were acquired through restricted stock vesting on March 15, 2023, and February 15, 2024.
Investing.com reported that State Street Corp (STT) filed a Form 144 for October 26. This filing typically indicates an insider's intent to sell restricted or control securities. The article includes the stock ticker STT and its current performance of +2.21%.
Key Takeaways SoFi's Q3 earnings are expected to rise 54.55%, with revenues growing 32.36% on higher customer activity.SoFi's 15.8 million members, rising product adoption and strong lending demand could fuel...
Peter J. Federico, an officer and director of AGNC Investment Corp., has filed a Form 144 notice for the proposed sale of 67,794 shares of common stock with an aggregate market value of $601,357.52. The shares were acquired through restricted stock vesting on March 15, 2023, and February 15, 2024. This filing indicates that Federico does not know of any material adverse non-public information regarding AGNC Investment Corp.
This article from Investing.com announces a Form 144 filing for Quest Diagnostics Inc., pertaining to transactions made on October 26th. It briefly mentions the company's stock symbol DGX and includes a Reuters copyright notice, but provides no further details on the nature of the filing.
See more of our coverage in your search results. Check please! Social Security recipients will see an “extra” payment this month — kind of. Supplemental Security Income (SSI) is a...
This article announces the filing of Form 144 for Quest Diagnostics Inc. on October 26, 2026. Form 144 is a notice of the intent to sell restricted securities. The brief notice indicates a transaction involving DGX stock.
Xencor Inc.'s stock recently reached a 52-week high of $32.29, currently trading at $32.83, indicating strong market performance and investor confidence with a 90.61% return over the past year. Truist Securities also raised its price target for Xencor to $29 from $27, maintaining a Buy rating ahead of an important update regarding XmAb819 at the ESMO event. Despite appearing overvalued by InvestingPro, these developments highlight potential growth prospects for the biotech company.
Wells Fargo & Company has increased its price target for Apple Hospitality REIT (NYSE:APLE) to $18 from $17, maintaining an "equal weight" rating. This adjustment comes as the company's shares rose 1.8% to $18.36 after exceeding quarterly earnings and revenue estimates. Despite mixed analyst sentiment, with a consensus "Hold" rating, several firms have recently upgraded the stock or raised their price targets.
Gold prices were little changed near $4,000 an ounce on Monday after hitting a more than three-month low of $3,975 on Friday, as falling oil prices eased inflation concerns ahead of this week’s central bank meetings.Oil retreated from last week’s surge but remained near six-month highs amid hopes o...
FICO has announced it will maintain its wholesale mortgage score bundle price at $10 for lenders and brokers participating in its Preferred Program, covering both Classic FICO and FICO Score 10T. This decision comes as the mortgage industry prepares for a multiyear transition in conventional mortgage credit score requirements, with competitors like VantageScore 4.0 offered at a lower price point. The move aims to ensure lenders have access to trusted tools for risk assessment amidst evolving policy discussions around credit report usage in mortgage underwriting.
This article demonstrates the power of compounded returns by showing the hypothetical growth of a $100 investment in Royal Caribbean Group (NYSE: RCL) stock over 15 years. Royal Caribbean Group has outperformed the market, achieving an average annual return of 16.87% during this period. A $100 investment made 15 years ago would now be worth $950.98.
Pamela S. Hershberger, a director at Andersons (ANDE), acquired additional restricted share units (RSUs) on October 22, 2026, described as dividend equivalents. She received 9.839 RSUs for 2024, 7.209 for 2025, and 10.423 for 2026, which grant her the right to receive one common share upon vesting for each unit. Following these transactions, her total RSU balances adjusted, and she directly holds over 14,000 shares of common stock.